Assess whether labeling language overclaims the evidence (dc8d38)

Situation

A safety team sitting on a new disproportionate signal cannot treat an FAERS cluster in a demographic the trials under-enrolled as color commentary on biosimilar analytical similarity report. 505(b)(2) development lead must close labeling language overclaims the from that extract under Pharma & Life Sciences / Pharmacovigilance.

Decision

505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after an FAERS cluster in a demographic the trials under-enrolled.

Hypotheses to test

• Biosimilar analytical similarity report reads as Proceed under protocol once an FAERS cluster in a demographic the trials under-enrolled is lined up to the same Pharma & Life Sciences population.
• Biosimilar analytical similarity report is closer to Pause the pathway after an FAERS cluster in a demographic the trials under-enrolled; Proceed under protocol would over-claim this Pharmacovigilance extract.
• Escalate safety review is still live in biosimilar analytical similarity report for 505(b)(2) development lead in a safety team sitting on a new disproportionate signal.
• Biosimilar analytical similarity report is missing the fact 505(b)(2) development lead needs after an FAERS cluster in a demographic the trials under-enrolled; stop this Pharma & Life Sciences close.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on labeling language overclaims the.
• Check whether biosimilar analytical similarity report supports the labeled claim 505(b)(2) development lead would keep.
• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• For this Pharma & Life Sciences Pharmacovigilance file, read biosimilar analytical similarity report against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move labeling language overclaims the for 505(b)(2) development lead.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (biosimilar analytical similarity report after an FAERS cluster in a demographic the trials under-enrolled). Lead with the Pharma & Life Sciences option biosimilar analytical similarity report can support after an FAERS cluster in a demographic the trials under-enrolled, then the two facts that force it, then the Monday action for 505(b)(2) development lead in a safety team sitting on a new disproportionate signal.